Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report

Stock Track

02/13

Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.

The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.

These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1163537536"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163537536\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163537536?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163537536","market":"nz","top_or_hot":-1,"title":"Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report","media":"Stock Track","content":"<p>Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.</p><p>The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.</p><p>These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vertex Pharmaceuticals Soars 5.21% Intraday on Multiple Analyst Upgrades Following Earnings Report\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-13 22:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.</p><p>The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.</p><p>These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRTX","symbol_name":"福泰製藥","start_time":0,"source_url":"","article_id":"1163537536","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163537536","pubTimestamp":1770993370,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.The price increase follows a series of analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRTX":"福泰制药"},"translate_title":"个股追踪|Vertex Pharmaceuticals财报后多位分析师上调评级盘中飙升5.21%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1},"content_text":"Vertex Pharmaceuticals (VRTX) stock surged 5.21% during intraday trading on Friday, marking a significant upward movement for the biotechnology company.The price increase follows a series of analyst rating upgrades and price target increases from multiple financial institutions. Morgan Stanley maintained a Buy rating with a $570 price target, while Oppenheimer upgraded the stock to Outperform from Market Perform. Other firms including Scotiabank, HC Wainwright, Stifel, and Bernstein also raised their price targets for Vertex Pharmaceuticals.These positive analyst actions come after Vertex reported fourth-quarter earnings that showed revenue growth of 10% year-over-year to $3.19 billion and provided full-year 2026 revenue guidance of $12.95 billion to $13.1 billion. The company's diversified cystic fibrosis portfolio and pipeline developments appear to have generated optimism among analysts about its long-term growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}